Endothelial activation and chronic allograft rejection

Area of Science:

• Immunology
• Transplantation Biology
• Endothelial Cell Biology

Background:

• Microvascular endothelial cells play a key role in acute and hyperacute allograft rejection.
• Acute rejection involves increased cell adhesion and antigen presentation by inflamed graft endothelia.
• Hyperacute rejection is mediated by preformed antibodies binding to endothelial cells, initiating procoagulant activity.

Purpose of the Study:

• To investigate chronic allograft rejection as a third manifestation of endothelial cell activation.
• To explore whether different patterns of endothelial stimulation result in different manifestations of endothelial activation.
• To understand the role of endothelial cell-derived products in chronic rejection pathology.

Main Methods:

• Studies of acute rejection mechanisms in murine cardiac allografts.
• In vitro studies of human endothelial cell lines stimulated with steroids (prednisolone, dexamethasone) and interferon-gamma (IFN-γ).
• Analysis of endothelial cell expression of MHC class II and ICAM-1.

Main Results:

• Different stable endothelial phenotypes can develop during graft inflammation based on local immune stimuli.
• Steroids synergize with IFN-γ to enhance MHC class II expression on human endothelial cells.
• Steroids do not affect tumor necrosis factor-alpha (TNF-α)-induced endothelial behavior.

Conclusions:

• Chronic allograft rejection may result from persistent or periodic release of extracellular matrix components and growth factors by activated endothelial cells.
• Endothelial cell activation is a central mechanism in various forms of allograft rejection.
• Understanding endothelial cell responses to different stimuli is crucial for managing allograft rejection.